TY - JOUR
T1 - The unruptured intracranial aneurysm treatment score
T2 - A multidis ciplinary consensus
AU - Etminan, Nima
AU - Brown, Robert D.
AU - Beseoglu, Kerim
AU - Juvela, Seppo
AU - Raymond, Jean
AU - Morita, Akio
AU - Torner, James C.
AU - Derdeyn, Colin P.
AU - Raabe, Andreas
AU - Mocco, J.
AU - Korja, Miikka
AU - Abdulazim, Amr
AU - Amin-Hanjani, Sepideh
AU - Salman, Rustam Al Shahi
AU - Barrow, Daniel L.
AU - Bederson, Joshua
AU - Bonafe, Alain
AU - Dumont, Aaron S.
AU - Fiorella, David J.
AU - Gruber, Andreas
AU - Hankey, Graeme J.
AU - Hasan, David M.
AU - Hoh, Brian L.
AU - Jabbour, Pascal
AU - Kasuya, Hidetoshi
AU - Kelly, Michael E.
AU - Kirkpatrick, Peter J.
AU - Knuckey, Neville
AU - Koivisto, Timo
AU - Krings, Timo
AU - Lawton, Michael T.
AU - Marotta, Thomas R.
AU - Mayer, Stephan A.
AU - Mee, Edward
AU - Pereira, Vitor Mendes
AU - Molyneux, Andrew
AU - Morgan, Michael K.
AU - Mori, Kentaro
AU - Murayama, Yuichi
AU - Nagahiro, Shinji
AU - Nakayama, Naoki
AU - Niemelä, Mika
AU - Ogilvy, Christopher S.
AU - Pierot, Laurent
AU - Rabinstein, Alejandro A.
AU - Roos, Yvo B.W.E.M.
AU - Rinne, Jaakko
AU - Rosenwasser, Robert H.
AU - Ronkainen, Antti
AU - Schaller, Karl
AU - Seifert, Volker
AU - Solomon, Robert A.
AU - Spears, Julian
AU - Steiger, Hans Jakob
AU - Vergouwen, Mervyn D.I.
AU - Wanke, Isabel
AU - Wermer, Marieke J.H.
AU - Wong, George K.C.
AU - Wong, John H.
AU - Zipfel, Gregory J.
AU - Sander Connolly, E.
AU - Steinmetz, Helmuth
AU - Lanzino, Giuseppe
AU - Pasqualin, Alberto
AU - Rüfenacht, Daniel
AU - Vajkoczy, Peter
AU - McDougall, Cameron
AU - Hänggi, Daniel
AU - Leroux, Peter
AU - Rinkel, Gabriel J.E.
AU - Loch Macdonald, R.
N1 - Funding Information:
N. Etminan is a scientific advisor/officer for Edge Therapeutics, Inc. R. Brown, K. Beseoglu, S. Juvela, J. Raymond, A. Morita, and J. Torner report no disclosures relevant to the manuscript. C. Derdeyn serves on the Scientific Advisory Board for W. L. Gore and Associates and Pulse Therapeutics. He is a consultant for Penumbra Inc. (DSMB member) and Microvention (Angio Core Lab for brain aneurysm stent trial). A. Raabe, J. Mocco, M. Korja, A. Abdulazim, S. Amin-Hanjani, R. Al-Shahi Salman, D. Barrow, J. Bederson, A. Bonafe, and A. Dumont report no disclosures relevant to the manuscript. D. Fiorella is a consultant for Codman Neurovascular, Covidien/EV3, Sequent Medical, and Siemens Medical Imaging and received research support from Penumbra Inc. and Microvention. A. Gruber, G. Hankey, D. Hasan, B. Hoh, P. Jabbour, and H. Kasuya report no disclosures relevant to the manuscript. M. Kelly is a shareholder of Blockade Medical Inc. P. Kirkpatrick, N. Knuckey, T. Koivisto, T. Krings, M. Lawton, and T. Marotta report no disclosures relevant to the manuscript. S. Mayer is a consultant for Edge Therapeutics Inc. and Actelion Pharmaceuticals. E. Mee reports no disclosures relevant to the manuscript. V. Mendes Pereira is consultant for Covidien. A. Molyneux, M. Morgan, K. Mori, Y. Murayama, S. Nagahiro, N. Nakayama, M. Nimelä, C. Ogilvy, L. Pierot, A. Rabinstein, Y. Roos, J. Rinne, R. Rosenwasser, A. Ronkainen, K. Schaller, V. Seifert, R. Solomon, J. Spears, H.-J. Steiger, M. Vergouwen, I. Wanke, M. Wermer, G. Wong, J. Wong, G. Zipfel, E. Sander Connolly, and H. Steinmetz report no disclosures relevant to the manuscript. G. Lanzino is a consultant for Covidien, Edge Therapeutics, Inc., and Codman. A. Pasqualin, D. Rüfenacht, P. Vajkoczy, and C. McDougall report no disclosures relevant to the manuscript. D. Hänggi is a scientific advisor/officer for Edge Therapeutics, Inc. P. LeRoux is a Scientific Advisory Board member for Edge Therapeutics, Inc. and a consultant for Integra, Codman, Synthes, Neurologica, Brainsgate, and Orsan. G. Rinkel reports no disclosures relevant to the manuscript. R. Macdonald is Chief Scientific Officer of Edge Therapeutics, Inc. and received grant support from the Physicians Services Incorporated Foundation, Brain Aneurysm Foundation, Canadian Institutes for Health Research, and the Heart and Stroke Foundation of Canada. Go to Neurology.org for full disclosures.
Publisher Copyright:
© 2015 American Academy of Neurology.
PY - 2015/9/8
Y1 - 2015/9/8
N2 - Objective: We endeavored to develop an unruptured intracranial aneurysm (UIA) treatment score (UIATS) model that includes and quantifies key factors involved in clinical decision-making in the management of UIAs and to assess agreement for this model among specialists in UIA management and research. Methods: An international multidisciplinary (neurosurgery, neuroradiology, neurology, clinical epidemiology) group of 69 specialists was convened to develop and validate the UIATS model using a Delphi consensus. For internal (39 panel members involved in identification of relevant features) and external validation (30 independent external reviewers), 30 selected UIA cases were used to analyze agreement with UIATS management recommendations based on a 5-point Likert scale (5 indicating strong agreement). Interrater agreement (IRA) was assessed with standardized coefficients of dispersion (v r ) (v r 0 indicating excellent agreement and v r 1 indicating poor agreement). Results: The UIATS accounts for 29 key factors in UIA management. Agreement with UIATS (mean Likert scores) was 4.2 (95% confidence interval [CI] 4.1-4.3) per reviewer for both reviewer cohorts; agreement per case was 4.3 (95% CI 4.1-4.4) for panel members and 4.5 (95% CI 4.3-4.6) for external reviewers (p 0.017). Mean Likert scores were 4.2 (95% CI 4.1-4.3) for interventional reviewers (n 56) and 4.1 (95% CI 3.9-4.4) for noninterventional reviewers (n 12) (p 0.290). Overall IRA (v r ) for both cohorts was 0.026 (95% CI 0.019-0.033). Conclusions: This novel UIA decision guidance study captures an excellent consensus among highly informed individuals on UIA management, irrespective of their underlying specialty. Clinicians can use the UIATS as a comprehensive mechanism for indicating how a large group of specialists might manage an individual patient with a UIA.
AB - Objective: We endeavored to develop an unruptured intracranial aneurysm (UIA) treatment score (UIATS) model that includes and quantifies key factors involved in clinical decision-making in the management of UIAs and to assess agreement for this model among specialists in UIA management and research. Methods: An international multidisciplinary (neurosurgery, neuroradiology, neurology, clinical epidemiology) group of 69 specialists was convened to develop and validate the UIATS model using a Delphi consensus. For internal (39 panel members involved in identification of relevant features) and external validation (30 independent external reviewers), 30 selected UIA cases were used to analyze agreement with UIATS management recommendations based on a 5-point Likert scale (5 indicating strong agreement). Interrater agreement (IRA) was assessed with standardized coefficients of dispersion (v r ) (v r 0 indicating excellent agreement and v r 1 indicating poor agreement). Results: The UIATS accounts for 29 key factors in UIA management. Agreement with UIATS (mean Likert scores) was 4.2 (95% confidence interval [CI] 4.1-4.3) per reviewer for both reviewer cohorts; agreement per case was 4.3 (95% CI 4.1-4.4) for panel members and 4.5 (95% CI 4.3-4.6) for external reviewers (p 0.017). Mean Likert scores were 4.2 (95% CI 4.1-4.3) for interventional reviewers (n 56) and 4.1 (95% CI 3.9-4.4) for noninterventional reviewers (n 12) (p 0.290). Overall IRA (v r ) for both cohorts was 0.026 (95% CI 0.019-0.033). Conclusions: This novel UIA decision guidance study captures an excellent consensus among highly informed individuals on UIA management, irrespective of their underlying specialty. Clinicians can use the UIATS as a comprehensive mechanism for indicating how a large group of specialists might manage an individual patient with a UIA.
UR - http://www.scopus.com/inward/record.url?scp=84951316257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951316257&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000001891
DO - 10.1212/WNL.0000000000001891
M3 - Article
C2 - 26276380
AN - SCOPUS:84951316257
SN - 0028-3878
VL - 85
SP - 881
EP - 889
JO - Neurology
JF - Neurology
IS - 10
ER -